Hengrui Medicine (01276.HK) subsidiary received approval from the National Medical Products Administration for the issuance of the "Drug Clinical Trial Approval Notice" for SHR-3079 injection.

Wisdom Financial News APP News, Hengrui Medicine (01276.HK) announced that recently, its subsidiary Suzhou Shengdiya Biopharmaceutical Co., Ltd. received the approval notice for the drug clinical trial of SHR-3079 injection issued by the National Medical Products Administration (NMPA), and will soon start clinical trials.